Back to Dashboard








Moderna, Inc. (MRNA)
Real-time intraday values
Market Overview
From:
To:
MRNA Intraday
No data available
SymbolMRNA
IPO DateDec 7, 2018
CEOMr. Stéphane Bancel M.B.A.
Full Time Employees4.7k
SectorHealthcare
IndustryBiotechnology
CountryUnited States
ExchangeNasdaqGS
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +6.25% | +3.26 US$ |
| 5 Days | +11.58% | +5.75 US$ |
| 1 Month | +12.95% | +6.35 US$ |
| 6 Months | +81.55% | +24.88 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of MRNA...
Key Statistics
Market Cap
21.98B
P/E Ratio
N/A
Div Yield
N/A
52W High
$59.55
52W Low
$22.28
Analyst Consensus
ConsensusHold
Bullish313.0%
Neutral1669.6%
Bearish417.4%
52W Analyst Price Targets
Min Target
$21.00
$21.00
Max Target
$69.00
$69.00
Current$55.39
Avg Target$43.30
Analyst Recommendations
Target Price:$43.30($21.00 - $69.00)
Community Thoughts
Share your analysis and sentiment on MRNA
Join the community to share your analysis
Latest News for MRNA
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
24/7 Wall St.•Jun 16, 2026, 07:21 PM
Moderna Surges On This Surprising FDA View For Its mRNA-Based Flu Shot
Investor's Business Daily•Jun 16, 2026, 08:06 PM
US Equity Markets End Mixed as Dow Hits Record High Amid Lower Crude Oil Prices, Tech Stock Sell-Off
MT Newswires•Jun 16, 2026, 08:16 PM
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
GlobeNewswire•Jun 16, 2026, 11:01 AM
SpaceX, Western Digital, Moderna, and More Stocks That Explain Today’s Market
Barrons.com•Jun 16, 2026, 06:33 PM
A Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The Pack
StockStory•Jun 16, 2026, 06:33 PM
Pluristyx Announces Patent Allowance of Next Generation Synthetic mRNA Technology in Japan, Solidifying Global iPSC Reprogramming Leadership
GlobeNewswire•Jun 16, 2026, 11:07 AM
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
ACCESS Newswire•Jun 16, 2026, 11:30 AM
Pew Supports 10 Leading Latin American Scientists
PR Newswire•Jun 16, 2026, 03:04 PM